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Summary
 
Trichosanthin (TCS), an active protein component isolated from a traditional Chinese medici-
nal herb
 
 Trichosanthes kirilowii
 
, has been shown to inhibit HIV infection and has been applied in
clinical treatment of AIDS. The recent development that chemokines and chemokine receptors
play important roles in HIV infection led us to investigate the possible functional interaction of
TCS with chemokines and their receptors. This study demonstrated that TCS greatly enhanced
both RANTES (regulated upon activation, normal T cell expressed and secreted)– and stromal
 
cell–derived factor (SDF)-1
 
a
 
–stimulated chemotaxis (EC
 
50 
 
> 
 
1 nM) in leukocytes (THP-1, Jur-
kat, and peripheral blood lymphocyte cells) and activation of pertussis toxin–sensitive
 
 
 
G proteins
 
(EC
 
50
 
 
 
> 
 
20 nM). TCS also significantly augmented chemokine-stimulated activation of chemo-
kine receptors CCR5 and CXCR4 as well as CCR1, CCR2B, CCR3, and CCR4 transiently
expressed in HEK293 cells. A mutant TCS with 4,000-fold lower ribosome-inactivating activ-
ity showed similar augmentation activity as wild-type TCS. Moreover, flow cytometry demon-
strated that the specific association of TCS to the cell membranes required the presence of
chemokine receptors, and laser confocal microscopy reveals that TCS was colocalized with
chemokine receptors on the membranes. The results from TCS-Sepharose pull-down and TCS
and chemokine receptor coimmunoprecipitation and cross-linking experiments demonstrated
association of TCS with CCR5. Thus, our data clearly demonstrated that TCS synergizes activ-
ities of chemokines to stimulate chemotaxis and G protein activation, and the effects of TCS
are likely to be mediated through its interaction with chemokine receptors.
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T
 
richosanthin (TCS),
 
1
 
 a 27-kd protein, is an active com-
ponent extracted from the root tuber of Chinese me-
dicinal herb Tian-Hua-Fen (
 
Trichosanthes kirilowii
 
) of the
Cucurbitaceae family. In the classical Chinese medical ref-
erence work 
 
Compendium of Materia Medica
 
 written in the
late 14th century, Tian-Hua-Fen was documented as a drug
that resets menstruation and expels retained placentas, and
has been used in medical practice in China for hundreds of
years. In the early 1970s, TCS was isolated from 
 
T. kirilowii
 
and has been used to terminate early and midtrimester
pregnancies (1, 2) and to treat ectopic pregnancies, hydatidi-
form moles, and trophoblastic tumors (2, 3). Pharmacologi-
cal studies reported that TCS is able to inactivate eukaryotic
ribosomes (4, 5) and to suppress the immune responses (6, 7).
More interestingly, TCS was shown to inhibit HIV repli-
cation in infected cells of lymphocyte and mononuclear
phagocytic lineage, with no measurable toxicity in uninfected
cells (8, 9). In the early 1990s, TCS was applied in the treat-
ment of patients with AIDS or AIDS-related complex in
phase I and II studies (10–13). However, the underlying
mechanisms of the activities of TCS are not yet well-
understood.
Chemokines are a superfamily of small structurally re-
lated cytokine molecules characterized by their ability to
induce leukocyte migration and related responses (14–18).
Chemokines also play important roles in regulation of
 
1
 
Abbreviations used in this paper:
 
 DSS, disuccinimidyl suberate;
 
 
 
FBS, fetal
bovine serum; GPCR, G protein–coupled receptor; HA, hemagglutinin;
HEK, human embryonic kidney; MCP, monocyte chemotactic protein;
MIP, macrophage inflammatory protein; RANTES, regulated upon acti-
vation, normal T cell expressed and secreted; RIP, ribosome-inactivating
protein; SDF, stromal cell–derived factor; TCS, trichosanthin. 
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growth, and in angiogenic and developmental processes (14,
19–21). Biological activities of chemokines are mediated by
G protein–coupled chemokine receptors (GPCRs) classi-
fied as CC or CXC receptors based on the structures and
types of chemokines they interact with (14, 15). Of con-
siderable interest is the recent discovery that CC chemo-
kine receptors CCR5, CCR2B, and CCR3 and the CXC
chemokine receptor CXCR4 are the essential coreceptors
on the cell surface for HIV-1 fusion and infection (22–28).
Substantial progress has been made recently in the under-
standing of chemokine receptor–mediated cellular signaling
(29–32). Activation of chemokine receptors by chemokines
induces downregulation of chemokine receptors on the cell
surface (31, 32). Prevention of HIV-1 infection and inhibi-
tion of HIV-1 replication by chemokines, antagonists of
chemokine receptors, or mAbs to chemokine receptors,
which induce downregulation of chemokine receptors
and/or directly block HIV-1 interaction with the corecep-
tors, have been demonstrated (33–37). Therefore, drugs
that target chemokine receptors, the coreceptors of HIV,
have great potential in AIDS therapy.
This study was carried out in an attempt to understand
the cellular and molecular mechanisms of the activities of
TCS against HIV infection. Our results demonstrated that
TCS profoundly augments the ability of different chemo-
kines to activate a wide spectrum of chemokine receptors,
leading to chemotaxis and G protein activation, and that
the effect of TCS is likely to be mediated through its func-
tional interaction with these chemokine receptors.
 
Materials and Methods
 
Materials.
 
Recombinant human RANTES (regulated upon
activation, normal T cell expressed and secreted), macrophage
inflammatory protein (MIP)-1
 
b
 
, and monocyte chemotactic
protein (MCP)-1 were purchased from Sigma Chemical Co.,
and stromal cell–derived factor (SDF)-1
 
a
 
 was from PharMingen.
Native TCS was isolated from
 
 T. kirilowii
 
. Recombinant TCS
(r-TCS) and a mutant of TCS (m-TCS) were prepared as de-
scribed previously (38–40). The homogeneity of TCS prepara-
tions used was 
 
.
 
98%. Rabbit anti-TCS antibodies and an mAb
against TCS were provided by Prof. Ming Ye (Shanghai Institute
of Cell Biology). Mouse mAb 12CA5 against the influenza hem-
agglutinin (HA) epitope was obtained from Boehringer Mann-
heim. [
 
35
 
S]GTP
 
g
 
S and [
 
3
 
H]cAMP were purchased from Amersham
Pharmacia Biotech. MEM and RPMI 1640 were from GIBCO
BRL. GDP and GTP
 
g
 
S were from Sigma Chemical Co. CNBr-
activated Sepharose 4B was from Amersham Pharmacia Biotech.
 
Cloning.
 
CCR5 was cloned as described previously (32). The
full-length cDNA encoding CCR1, CCR2B, CCR3, CCR4,
and CXCR4 was cloned by reverse transcription PCR and PCR
from THP-1 cells (for CCR1, CCR2B, and CXCR4) or PBL
cells (for CCR3 and CCR4), using specific primers designed
from the published sequences (available from EMBL/GenBank/
DDBJ under accession nos. L09230, U03905, U28694, X85740,
and X71635). The amplified human chemokine receptor cDNA
fragments were then subcloned into a modified pcDNA3 vector
(Invitrogen) with the sequence of the HA epitope tag at the 5
 
9
 
end of the inserted receptor sequence. The authenticity of the re-
ceptor sequences was confirmed by DNA sequencing.
 
Cell Culture and Transfection.
 
THP-1 and Jurkat cells (Ameri-
can Type Culture Collection) were cultured in RPMI 1640
(GIBCO BRL) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS; GIBCO BRL), 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin, and 2 mM glutamine. PBMCs were obtained by the
Ficoll-Hypaque method from heparinized whole blood, and PBLs
were derived by serial depletion of adherent cells and maintained
in RPMI 1640 supplemented with 10–15% FBS. PBLs were
stimulated with 5 
 
m
 
g/ml phytohemagglutinin for 1 wk and main-
tained thereafter in the presence of IL-2. Human embryonic kid-
ney (HEK)293 cells (American Type Culture Collection) were
cultured in MEM supplemented with 10% heat-inactivated FBS,
100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 2 mM gluta-
mine. Transient transfection of HEK293 cells was performed using
4 
 
m
 
g DNA/10
 
6
 
 cells and the calcium phosphate–DNA coprecipi-
tation method, and the transfected cells were used 48 h after
transfection.
 
Chemotaxis Assay.
 
Chemotaxis was performed as described
previously (41, 42). In brief, cells were resuspended in RPMI
1640 containing 1 mg/ml BSA overnight in 5% CO
 
2
 
 at 37
 
8
 
C.
0.1 ml cells at 5 
 
3 
 
10
 
6
 
/ml were added to the top chamber of a
24-well transwell (6.5-mm diameter, 5-
 
m
 
m pore size; Corning
Costar) and incubated for 3 h or the time indicated at 37
 
8
 
C in 5%
CO
 
2
 
. Cells passing through the membrane were collected from
the lower well and counted by mixing a predetermined number
of yeast with the cells and running them through a FACSCali-
bur™ flow cytometer (Becton Dickinson). The yeast and the
cells were easily distinguishable on a side scatter vs. forward scat-
ter plot, which allowed the calculation of the ratio of yeast to
cells and the total number of cells that had migrated to the lower
wells. Cell numbers were also determined using a cell counter
and found to be in good agreement with the results from fluores-
cence-activated cell sorting.
 
[
 
35
 
S]GTP
 
g
 
S Binding Assay.
 
The assay was carried out as de-
scribed (43, 44). Cells were lysed in 5 mM Tris-HCl, pH 7.5, 5 mM
EDTA, and 5 mM EGTA at 4
 
8
 
C. After the lysate was centrifuged at
30,000 
 
g
 
 for 10 min, the membrane pellet was resuspended and ali-
quots containing 12 
 
m
 
g protein were incubated at 30
 
8
 
C for 1 h in 50
mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 5 mM
MgCl
 
2
 
, 100 mM NaCl, 40 
 
m
 
M GDP, and 0.5 nM [
 
35
 
S]GTP
 
g
 
S
(1,200 Ci/mmol) in the presence or absence of the agonists in a
total volume of 100 
 
m
 
l. The reaction was terminated by adding cold
PBS and filtering through GF/C filters. Radioactivity of each
sample was measured in a liquid scintillation spectrophotometer.
Data were means of duplicate samples. Basal binding was deter-
mined in the absence of agonists, and nonspecific binding was
obtained in the presence of 10 
 
m
 
M GTP
 
g
 
S. The percentage of
stimulated [
 
35
 
S]GTP
 
g
 
S binding was calculated as 100 
 
3 
 
(cpm
 
sample 
 
2
 
cpm
 
nonspecific
 
)/(cpm
 
basal 
 
2
 
 cpm
 
nonspecific
 
).
 
cAMP Assay.
 
Cells were challenged with agonists in the
presence of 10 
 
m
 
M forskolin (Sigma Chemical Co.) and 500 
 
m
 
M
1-methyl-3-isobutylxanthine (IBMX; Sigma Chemical Co.) at
37
 
8
 
C for 10 min. The reaction was terminated with 1 N perchlo-
ric acid and then neutralized with 2 M K
 
2
 
CO
 
3
 
. The cAMP
level of each sample was determined using radioimmunoassay as
described previously (45–47). Data were averages of duplicate
samples and were presented as a percentage of control, calculated
as 100 
 
3 
 
[cAMP
 
(forskolin 
 
1
 
 agonist) 
 
2
 
 cAMP
 
(basal)
 
]/[cAMP
 
(forskolin)
 
 
 
2
 
cAMP
 
(basal)
 
]. cAMP
 
(forskolin 
 
1
 
 agonist)
 
 is cAMP accumulation in the
presence of forskolin and agonist, cAMP
 
(basal)
 
 is cAMP accumula-
tion in the absence of forskolin and agonist, and cAMP
 
(forskolin)
 
 is
cAMP accumulation in the presence of forskolin alone.
 
Flow Cytometry.
 
Cells were incubated with TCS (100 nM) in 
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PBS containing 2% BSA at 4
 
8
 
C for 1 h and, after washing with
PBS, were incubated with 12CA5 (5 
 
m
 
g/ml) and rabbit TCS-
specific antibodies (1:1,000) in PBS containing 2% BSA at 4
 
8
 
C
for 1 h. The presence of HA-tagged chemokine receptors and
TCS on the cell surface was detected by incubation with FITC-
conjugated, affinity-purified goat anti–mouse IgG (Tago) and tet-
ramethyl-rhodamine isothiocyanate (TRITC)-conjugated goat
anti–rabbit IgG (Jackson ImmunoResearch Labs). The cells were
analyzed on a FACSCalibur™ flow cytometer. Basal cell fluores-
cence intensity was determined with cells stained with the sec-
ondary antibody alone.
 
Immunofluorescence Microscopy.
 
As described previously (48, 49),
cells grown on coverslips were fixed in 1% polyformaldehyde for
20 min. After incubation with TCS (100 nM) in PBS containing
2% BSA at 4
 
8
 
C for 1 h and washing twice with cold PBS, cells
were treated with 12CA5 mAb and rabbit anti-TCS antibodies.
The presence of HA-tagged chemokine receptors and TCS in the
cells was then detected with FITC-conjugated, affinity-purified
goat anti–mouse IgG and Texas Red–conjugated, affinity-puri-
fied goat anti–rabbit IgG (Amersham Pharmacia Biotech), respec-
tively. In addition, control experiments with mock transfection,
or in the absence of the first antibodies, or without TCS were
performed. Images were recorded using a Leica TCS NT laser
confocal scanning microscope.
 
SDS-PAGE and Silver Staining.
 
The experiment was performed
by using a modified silver stain process. 5 
 
m
 
g purified protein was
loaded to 12% SDS-PAGE. The gel was then prefixed with 30%
ethanol and 10% acetic acid (HAc) and fixed in 30% ethanol, 0.4 M
NaAc, pH 6.0, and 0.03% Na
 
2
 
S
 
2
 
O
 
3
 
. After washing, the gel was
incubated in 0.1% AgNO
 
3
 
 and then in 2.5% Na
 
2
 
CO
 
3
 
 with 0.1%
Na
 
2
 
S
 
2
 
O
 
3
 
. The reaction was terminated by incubating the gel in
10% HAc.
 
Immunoprecipitation, Western Blotting, and Cross-linking Experi-
ments.
 
The immunoprecipitation experiment was performed as
described (50, 51). HEK293 cells grown in a 60-mm culture dish
were lysed in 0.8 ml IP buffer (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, and 0.4% digitonin) containing protease inhibitors on ice
for 45 min. The lysate was centrifuged at 12,000 
 
g
 
 for 30 min, and
the supernatants were incubated with the 12CA5 antibody (0.5 
 
m
 
g)
and protein A–Sepharose (GIBCO BRL) on ice for 2 h. TCS was
then added (0.5 
 
m
 
g) and incubated for another 2 h. After washing
with IP buffer, the immunocomplexes absorbed onto protein
A–Sepharose were eluted in SDS-PAGE sample buffer (50 mM
Tris-HCl, pH 7.4, 2% SDS, 5% 2-ME, 10% glycerol, and 0.01%
bromophenol blue) and subjected to 10% SDS-PAGE and West-
ern blot analysis. TCS present in the samples was detected using
rabbit anti-TCS antibodies, and the presence of CCR5 on the
same blot was detected using 12CA5 after stripping the antibodies
off by incubating in 62.5 mM Tris-HCl, pH 6.7, 100 mM 2-ME,
and 2% SDS at 70
 
8
 
C for 30 min.
Alternatively, the cell lysate prepared as described above was in-
cubated with TCS-coupled Sepharose or BSA-coupled Sepharose
(prepared following the manufacturer’s instructions) on ice for 4 h.
The supernatants were then discarded, the beads were lightly
washed, and the protein absorbed onto the beads was eluted in
SDS-PAGE sample buffer. SDS-PAGE and Western blot analysis
were performed as described above.
The cross-linking was performed by using disuccinimidyl sub-
erate (DSS; Pierce Chemical Co.) following the manufacturer’s
instructions. In brief, cells were lysed in 10 mM Hepes, pH 7.4,
5 mM EDTA, and 5 mM EGTA at 4
 
8
 
C. After the lysate was cen-
trifuged at 30,000 
 
g
 
 for 10 min, the membrane pellet was resus-
pended in PBS/Hepes (PBS containing 10 mM Hepes, pH 7.4).
 
The aliquots containing 500 
 
m
 
g membrane protein were then in-
cubated with or without DSS (100 
 
m
 
M) at room temperature for
30 min in the presence or absence of TCS (10 
 
mg) in a total vol-
ume of 400 ml. The reaction was terminated by adding cold 1 M
Tris-HCl (pH 7.4) to a final concentration of 10 mM and incu-
bating for an additional 15 min. The samples were analyzed using
Western blotting, and the cross-linked complex of TCS and
chemokine receptors was detected by rabbit anti-TCS antibodies.
Statistical Analysis. Each experimental point was performed in
duplicate, and at least three independent experiments were car-
ried out. Data are expressed as means 6 SE of all determinations.
Statistical significance of the experimental results was obtained by
Student’s t test. P , 0.05 was accepted as denoting statistical sig-
nificance.
Results
TCS Enhanced Chemokine-induced Chemotaxis in THP-1
Cells. Chemotaxis is the prototypic function of chemo-
kines, and thus serves as a biologically relevant functional in
vitro assay for chemokine receptor activation (41, 42). THP-1
cells are of human leukocyte origin and express functional
CCR1 (52), CCR5 (53), and CXCR4 (Zhao, J., and G.
Pei, unpublished observation), and therefore were used in the
chemotaxis experiments. THP-1 cells showed a classic bell-
shaped chemotactic response upon exposure to increasing
concentrations of either RANTES (Fig. 1 A) or SDF-1a
(Fig. 1 B), and both concentration–response curves reached
maximum at 1 nM of chemokine (Fig. 1, A and B). The
presence of 2 nM TCS alone did not significantly affect
chemotaxis (Fig. 1, A–C). However, cotreatment of 2 nM
TCS with RANTES or SDF-1a (0.1 nM and above)
strongly increased cell migration induced by either chemo-
kine (to z300% at chemokine concentrations of 1–10 nM).
The concentration–effect curves of TCS on chemokine-
induced chemotaxis show that a significant increase of
RANTES- and SDF-1a–stimulated chemotaxis occurred
Figure 1. Enhancement of RANTES- and SDF-1a–induced chemo-
taxis by TCS in THP-1 cells. Cells were challenged with RANTES
(RAN, A) or SDF-1a (SDF, B) at concentrations indicated in the pres-
ence or absence of 2 nM TCS at 378C for 3 h, and the chemotaxis was
determined as described in Materials and Methods. THP-1 cells were in-
cubated with different concentrations of TCS (C) in the absence or pres-
ence of 1 nM RANTES or 1 nM SDF-1a at 378C for 3 h, and the mi-
grated cells were collected and counted as described above. Data were
mean 6 SE of two independent experiments performed in duplicate.104 Trichosanthin Enhances Chemokine Receptor Activation
at TCS concentrations of as low as 0.5 nM, and 2 nM TCS
resulted in the maximal enhancement of z250% (Fig. 1 C).
TCS Enhanced Chemokine-induced G Protein Activation in
THP-1 Cells. Our previous study demonstrated that stimu-
lation of chemokine receptors by their agonists activates mem-
brane-associated Gi/Go proteins using [35S]GTPgS binding
assay (32). As shown in Fig. 2, A and B, RANTES (agonist of
both CCR1 and CCR5) and SDF-1a (agonist of CXCR4)
activated membrane-associated G proteins in a concentra-
tion-dependent manner in THP-1 cells. TCS (0.2 mM)
alone did not have a significant effect on [35S]GTPgS bind-
ing. But interestingly, in the presence of 0.2 mM TCS,
RANTES- or SDF-1a–stimulated G protein activation in-
creased significantly and the maximal stimulation induced
by RANTES and SDF-1a increased by 150 and 200%,
respectively (Fig. 2, A and B). As shown in Fig 2 C, the
ability of TCS to enhance chemokine RANTES- and
SDF-1a–induced G protein activation was dependent on
TCS concentration (EC50 > 20 nM). At 5 nM or higher
concentration, TCS showed a significant enhancement
effect, and in the presence of 200 nM TCS, RANTES- and
SDF-1a–induced chemokine receptor stimulation increased
by two- to threefold. TCS alone did not have a significant
effect on basal [35S]GTPgS binding (Fig. 2 C).
TCS Augmented Chemokine-induced Signaling in PBLs and
Jurkat Cells. To test whether TCS can enhance the capabil-
ity of chemokine to activate chemokine receptors in other
cells, PBLs and Jurkat cells were used in this study. As shown
in Fig. 3, A and B, TCS significantly enhanced the activa-
tion of G proteins induced by RANTES, MCP-1, and
SDF-1a in PBLs and by RANTES and SDF-1a in Jurkat
cells, respectively. Neither MCP-1 alone nor MCP-1 plus
TCS resulted in any stimulation of G protein activation in
Jurkat cells that lack CCR2, the receptor of MCP-1. This
indicates that the specificity of the effects of TCS relies on
both chemokine and chemokine receptor. In the chemo-
taxis assay, TCS also increased the efficacies of RANTES
and MCP-1 to induce cell migration in PBLs (Fig. 3 C)
and of RANTES and SDF-1a in Jurkat cells (Fig. 3 D).
These data clearly demonstrate that TCS enhances the abil-
ity of chemokines to stimulate chemokine receptors and to
induce chemotaxis in leukocytes.
The Effects of TCS Were Chemokine Receptor Dependent and
Required G Proteins. In HEK293 cells transiently expressing
CCR5 (Fig. 4, A and C) or CXCR4 (Fig. 4, B and D),
TCS significantly enhanced both RANTES- and SDF-1a–
stimulated G protein activation. The effect of TCS in these
cells was chemokine concentration and TCS concentration
dependent. However, in the mock-transfected HEK293
cells, neither was chemokine-stimulated [35S]GTPgS bind-
ing observed nor did TCS show any augmentation effects
when used together with RANTES or SDF-1a under the
same conditions. In addition, MCP-1, an agonist of CCR2,
in either the absence or presence of TCS, was not able to
stimulate G protein activation in HEK293 cells transfected
with CCR5 (data not shown). Chemokine receptors are able
to couple to Gi and Gq proteins. Activation of chemokine
receptors causes activation of membrane-associated G pro-
teins and results in inhibition of adenylyl cyclase. As shown
in Fig. 5, RANTES and SDF-1a caused inhibition of
adenylyl cyclase activity in HEK293 cells transiently ex-
pressing CCR5 or CXCR4. Coapplication of TCS under
such conditions considerably increased the efficacies of both
Figure 2. Enhancement of
RANTES- and SDF-1a–stimu-
lated G protein activation by TCS
in THP-1 cells. The cell mem-
branes were challenged with dif-
ferent concentrations of RANTES
or SDF-1a in the absence or pres-
ence of 0.2 mM TCS at 308C for
60 min (A and B) or with none or
10 nM RANTES or SDF-1a in
the presence of different concen-
trations of TCS at 308C for 60 min
(C). The [35S]GTPgS binding of
each sample was measured as
described in Materials and Meth-
ods. Data were mean 6 SE of
three independent experiments
performed in duplicate.
Figure 3. The enhancement effects of TCS on chemokine-stimulated
G protein activation and chemotaxis in PBLs and Jurkat cells. PBLs (A
and C) and Jurkat cells (B and D) were stimulated with RANTES, MCP-1,
or SDF-1a in the absence or presence of TCS (0.2 mM for [35S]GTPgS
binding and 2 nM for chemotaxis), and [35S]GTPgS binding of cell mem-
branes and number of cells migrated for each sample were determined as
described in Materials and Methods. Data were mean 6 SE of at least two
independent experiments performed in duplicate.105 Zhao et al.
chemokines to inhibit cellular cAMP production (Fig. 5).
Chemokine-induced inhibition of cAMP production and
the enhancement of this by TCS were abolished by pertussis
toxin (data not shown). The above results further demon-
strate the indispensability of both chemokines and the cor-
responding chemokine receptors for TCS to exert its effects.
The Effects of TCS Extended to Many Other Chemokine Re-
ceptors. To test the potential effects of TCS on cellular sig-
naling mediated by other chemokine receptors and GPCRs
in addition to CCR5 and CXCR4, chemokine receptors
CCR1, CCR2B, CCR3, and CCR4 and k and d opioid
receptor were transiently expressed in HEK293 cells. As
shown in Fig. 6, TCS significantly enhanced G protein ac-
tivation mediated by CCR1, CCR2B, CCR3, and CCR4,
but failed to enhance opioid agonist–induced G protein ac-
tivation mediated by either k (Fig. 6) or d opioid receptor
(data not shown). The above data suggest that in addition
to CCR5 and CXCR4, TCS could exert its effect on other
members of the chemokine receptor family, probably via a
similar mechanism, but the effect of TCS is chemokine
receptor specific and may not extend to other peptide Gi/
Go-coupled receptors.
The Effects of TCS on Chemokine Receptor Activation Were
Independent of Its Ribosome-inactivating Activity. As shown in
Fig. 6, after denaturation, TCS lost its ability to enhance
chemokine receptor–mediated G protein activation. Further-
more, the enhancement effects of TCS were also blocked
by preincubation with the purified mAb against TCS (data
not shown). These experiments indicate that TCS is respon-
sible for the observed magnification of chemokine-induced
signaling. TCS was originally isolated from T. kirilowii, and
the recombinant TCS with comparable activities was later
successfully produced from Escherichia coli (38, 39). As shown
in Fig. 7, r-TCS compared with native TCS conferred in-
distinguishable magnification effects on the chemokine-
induced G protein activation and chemotaxis of leukocytes.
These data argue that it is the presence of TCS, not any
impurities from the preparation, that causes the observed
effects on chemokine receptor activation and provides the
molecular basis for structure–function studies of TCS.
TCS has been identified as a type I ribosome-inactivating
protein (RIP) with a wide spectrum of biological and phar-
macological activities. Recent studies showed that mutation
at position 120–123 (Lys-Ile-Arg-Glu to Ser-Ala-Gly-Gly)
in TCS causes a 4,000-fold decrease in ribosome-inactivating
activity (54), implying that this region of the TCS molecule
plays a critical role in maintaining its ribosome-inactivation
activity. However, this very mutant of TCS (m-TCS) showed
similar, or perhaps even higher, enhancement on chemo-
Figure 4. The enhancement effect of TCS
in HEK293 cells expressing CCR5 or
CXCR4. The cell membranes from CCR5 (A
and C) or CXCR4 (B and D) transfected cells
were stimulated with different concentrations
of RANTES (A) or SDF-1a (B) in the absence
or presence of 0.2 mM TCS, or incubated with
different concentrations of TCS in the presence
of 10 nM RANTES (C) or SDF-1a (D). The
[35S]GTPgS binding of each sample was then
measured as described in Materials and Meth-
ods. Data were mean 6 SE of three indepen-
dent experiments performed in duplicate.
Figure 5. Augmentation of
RANTES- or SDF-1a–induced
inhibition of cAMP accumulation
by TCS. HEK293 cells transfected
with CCR5 (A) or CXCR4 (B)
were treated by different concen-
trations of RANTES or SDF-1a
in the presence or absence of 0.2
mM TCS at 378C for 10 min, and
the cellular cAMP level was mea-
sured as described in Materials and
Methods. Data were mean 6 SE
of three independent experiments
performed in duplicate.106 Trichosanthin Enhances Chemokine Receptor Activation
kine-induced G protein activation and chemotaxis of leuko-
cytes compared with native TCS (Fig. 7). These results
indicate that residues 120–123 of TCS required for its ribo-
some-inactivation activity are not essential for the enhance-
ment effects of TCS in the chemokine receptor–mediated
signaling, and suggest that the effects of TCS we observed
in this study are not related to its ribosomal inactivation.
Colocalization of TCS with Chemokine Receptors on the Mem-
brane, and Interaction of TCS with Chemokine Receptors. The
ability of TCS to synergize chemokine-induced chemotaxis
and G protein activation requires the presence of the chemo-
kine receptors and may be accomplished through direct in-
teraction of TCS with chemokine receptors on the mem-
brane. To test this possibility, HEK293 cells were transiently
transfected with control vector or HA-tagged CCR5 and
incubated with or without 0.1 mM TCS. The HA-tagged
chemokine receptors were labeled by staining the cells with
12CA5 and FITC-conjugated anti–mouse IgG, and TCS on
the cell surface was detected with rabbit anti-TCS antibodies
and TRITC-conjugated anti–rabbit secondary antibody.
The results from flow cytometry are shown in Fig. 8 (A–D):
typically, z30% of CCR5-transfected cells expressed CCR5
on the cell surface and were stained FITC fluorescence posi-
tive (Fig. 8 C). Strong TCS-specific TRITC fluorescence
signal was detected in the CCR5-expressing cells (Fig. 8 D),
and no significant positive TCS-like TRITC fluorescence
was observed in the control vector–transfected cell popula-
tion (Fig. 8 B). The immunofluorescence staining of TCS
was also detected in the HEK293 cells expressing CXCR4
but not in the control cells (data not shown). These results
indicate that the presence of chemokine receptors is a pre-
requisite for TCS binding to the cell surface.
The location of TCS and chemokine receptors on the sur-
face of the cells expressing CCR5 and CXCR4 was visual-
ized under a laser scanning confocal fluorescence microscope
after staining with anti-TCS/anti–rabbit IgG–Texas Red
and 12CA5/anti–mouse IgG–FITC. The visible binding of
TCS (Fig. 8, F and I) was only observed on the surface of
the cells expressing either CCR5 (Fig. 8 E) or CXCR4 (Fig.
8 H), and it appeared, in more detail, that TCS was local-
ized on the cell surface at the sites where the chemokine
receptor CCR5 (Fig. 8 G) or CXCR4 resides (Fig. 8 J).
Finally, the interaction between TCS and chemokine re-
ceptors was investigated using several approaches. As shown
in Fig. 9 A, chemokine receptor CCR5 in cell lysate was
pulled down by the TCS-Sepharose but not by the BSA-
Sepharose. Experiments done with chemokine receptor
CXCR4 gave similar results (data not shown). Coimmuno-
precipitation of TCS with chemokine receptors was also
detected (Fig. 9, B and C). In cross-linking experiments,
incubation of TCS and membranes containing CCR5 with
DSS resulted in an upshift of the TCS band to z70 kd, ap-
proximately the sum of TCS (29 kd) and CCR5 (50 kd)
(Fig. 9 D). These results indicate that specific association of
TCS to the cell membranes requires the presence of chemo-
kine receptors, and that the synergic effects of TCS on
chemotaxis and G protein activation induced by chemo-
kines may be a result of direct interaction of TCS with
chemokine receptors.
Discussion
TCS has been used in the clinical treatment of patients
with AIDS or AIDS-related syndromes, but its underlying
mechanisms are not well-understood. Recent discoveries
that the chemokine receptors CCR5, CXCR4, CCR2B,
and CCR3 are HIV-1 coreceptors have thrown new light
on the combat against AIDS and other viral diseases. In this
work, the effects of TCS on chemokine-stimulated chemo-
taxis and cellular signaling events and the potential interac-
tion of TCS with the chemokine receptors were investigated.
Our results demonstrated that TCS significantly enhanced
the chemokine-induced leukocyte chemotaxis, and that the
Figure 6. TCS enhances chemokine receptor–mediated G protein ac-
tivation. Membranes from THP-1 and HEK293 cells transiently trans-
fected with chemokine receptors CCR1, CCR2B, CCR3, or CCR4, or
k opioid receptor (KOR) were challenged with RANTES, MIP-1b,
MCP-1, or SDF-1a in the absence or presence of 0.2 mM TCS or de-
TCS (TCS denatured at 608C for 20 min) at 308C for 60 min as indi-
cated. The [35S]GTPgS binding of each sample was then measured as de-
scribed in Materials and Methods. Data were mean 6 SE of three
independent experiments performed in duplicate.107 Zhao et al.
effect of TCS was primarily due to its ability to synergize
chemokine-dependent activation of chemokine receptors
and subsequent receptor-mediated signaling. Our data also
revealed the specific association of TCS to the cell mem-
branes with the expression of chemokine receptors and the
colocalization and coimmunoprecipitation of TCS with
chemokine receptors, suggesting the possibility of direct in-
teraction of TCS with chemokine receptors. Furthermore,
the mutant TCS, which lacks the ribosome-inactivating ac-
tivity, possessed similar enhancement activity as wild-type
TCS. Taken together, these results brought to light that
TCS was able to functionally interact with a broad spectrum
of chemokine receptors as a potent coactivator, which may
be one of the mechanisms underlying application of TCS
in AIDS treatment.
Although our results demonstrated that TCS functionally
interacts with chemokine receptors and is colocalized with
the receptors on the cell surface, it remains unclear how TCS
is able to costimulate the activation of many different kinds of
chemokine receptors by their corresponding chemokines
(such as RANTES, SDF-1a, MIP-1b, and MCP-1). One
possibility could be that TCS induces the conformational
change of chemokine receptors through direct physical
contact at the putative binding site that possesses a common
structural feature shared by these receptors. Alternatively,
TCS may exert its effects through indirect interaction with
a third partner on the cell surface, forming a complex capa-
ble of interacting with chemokine receptors. Our data sug-
Figure 7. The effects of mutant TCS on chemokine receptor activation and chemotaxis. THP-1 cells were stimulated with SDF-1a (10 nM) in the
absence or presence of TCS (isolated from T. kirilowii), r-TCS (recombinant TCS expressed in E. coli), or m-TCS (mutation at position 120–123) (0.2 mM
for [35S]GTPgS binding and 2 nM for chemotaxis). [35S]GTPgS binding (A) and chemotaxis (B) were determined as described in Materials and Meth-
ods. Data were mean 6 SE of at least two independent experiments performed in duplicate. The purities of TCS, r-TCS, and m-TCS were examined
using silver staining after SDS-PAGE (C).
Figure 8. Colocalization of TCS with chemokine receptors on cell
surface. The HEK293 cells transiently transfected with HA-tagged CCR5
were incubated without (A and B) or with (C and D) 0.1 mM TCS at
48C for 1 h. The cells were then stained with 12CA5 and FITC-conju-
gated anti–mouse IgG for transfected CCR5 and with rabbit anti-TCS
antibodies and TRITC-conjugated anti–rabbit IgG for TCS. The samples
were analyzed by flow cytometry for FITC-labeled (A and C) and
TRITC-labeled (B and D) fluorescence signals on the cell surface. Simi-
larly, colocalization of TCS with chemokine receptor on the cell surface
was examined by laser confocal fluorescence microscopy (E–J). The cells
transiently expressing CCR5 (E–G) or CXCR4 (H–J) were stained with
12CA5/anti–mouse IgG–FITC (for expressed receptor) and anti-TCS/
anti–rabbit IgG–Texas Red (for TCS); FITC (green, E and H), Texas
Red (red, F and I), and FITC and Texas Red overlapping (yellow, G and
J) fluorescent images from the same view were then visualized. Untrans-
fected cells or mock-transfected cells showed negative staining under the
same conditions (data not shown).108 Trichosanthin Enhances Chemokine Receptor Activation
gest that on these chemokine receptors, the putative associ-
ation site(s) at which TCS directly or indirectly interacts
appears distinct from the site(s) associated with the chemo-
kines. It has been shown that gp120 envelope glycoproteins
of human HIV-1 can physically and functionally interact
with chemokine receptors (36, 55–57), and on the recep-
tors the association site(s) of gp120 apparently overlaps with
the site(s) associated with the chemokines, since gp120 is
able to displace chemokines. Very recent reports from x-ray
crystal studies have revealed the structural determinants of
gp120 for its binding to CCR5 (58). Similar approaches will
be helpful in determining the structural domain of TCS
essential for its association with chemokine receptors, since
x-ray structural information for TCS is already available
(59–61).
Several members of the chemokine receptor family func-
tion in association with CD4 to permit entry and infection
of HIV-1. CCR5 is a major fusion coreceptor for macro-
phage-tropic HIV-1 isolates, and CXCR4 is a coreceptor
for the entry of T cell line–tropic HIV-1 strains. Chemo-
kines have been shown to inhibit HIV-1 infection, though
inefficiently, by interacting with chemokine receptors and
thus preventing HIV-1 from using the coreceptors (62, 63).
However, the clinical use of excess amounts of chemo-
kines, which induce chemotaxis and activation of leukocytes,
may result in undesirable inflammatory side effects. Re-
cently, a CCR5 antagonist from RANTES derivatives has
been shown in vitro to block HIV-1 infection of macro-
phage and lymphocytes at nanomolar concentration (34).
Searching for potent antagonists of chemokine receptors is
now popularly considered and heavily pursued as one of
the most promising strategies for HIV therapy. The result
from this study that TCS strongly enhanced the ability of
chemokines to activate their receptors may further provide
another useful approach to inhibit HIV infection. One of
the potential advantages of using coactivators such as TCS
could be that the agents, which are not agonists or antago-
nists, can effectively interact with a wide spectrum of chemo-
kine receptors and may thus promote the efficiency of var-
ious endogenous chemokines in blocking HIV infection. It
is also worth mentioning that very little about the coactiva-
tor(s) of GPCRs has been reported to date. Therefore, the
enhancement effects of TCS on chemokine receptor activa-
tion may offer a good working model for augmenting our
understanding of GPCR activation.
Trichosanthin is a member of the type I RIPs with RNA
N-glycosidase activity. It has been reported that TCS inhibits
HIV replication in vitro in acutely and chronically infected
lymphocytes and monocytes (9). Clinical studies also show
that TCS treatment may help to prevent loss of CD41 cells
in AIDS patients failing treatment with antiretroviral agents
such as zidovudine (10) and even to increase CD41 cells in
other cases (11, 12). It was speculated that the anti-HIV
effects of TCS might be due to its ribosome-inactivating
activity. However, studies suggest that the mechanism of
TCS to inhibit the replication and infection of HIV-1 is
different from its activities of ribosome inactivation and im-
munomodulation (40, 64). In addition, the undesirable side
effects of TCS, which have seriously limited its clinical ap-
plication, may also be related to its activity to induce un-
wanted cytotoxicities and allergic reactions. Our data in
this study showing that TCS greatly enhances activation of
chemokine receptors independent of its RIP activity may
not only reveal an alternative mechanism underlying the
anti-HIV effects of TCS but may also provide a mutagenesis
strategy potentially to improve its therapeutical effective-
ness and to reduce its side effects.
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Figure 9. Interaction of TCS and chemokine receptors. Lysates of mock- or CCR5-transfected HEK293 cells were incubated with TCS-Sepharose or
BSA-Sepharose, and the proteins absorbed onto these Sepharose beads were analyzed with 12CA5 after Western blotting (A). Lysate from mock- or
CCR5-transfected HEK293 cells was incubated with or without TCS and immunoprecipitated with 12CA5. The presence of CCR5 (B) and TCS (C)
in the immunocomplexes was detected with 12CA5 and anti-TCS antibodies after Western blotting. Purified TCS (1 ng) was loaded onto gel as a con-
trol. The cross-linking experiments were performed by incubating TCS with the membrane proteins extracted from mock- or CCR5-transfected cells as
described in Materials and Methods. The existence of TCS cross-linking to CCR5 was detected by rabbit anti-TCS antibodies, and immunoprecipita-
tion-purified CCR5 (detected by anti-12CA5 antibody) was shown for comparison (D).109 Zhao et al.
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